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Abstract
Objective: Seamless transition of endocrine patients from the paediatric to adult setting is still 
suboptimal, especially in patients with complex disorders, i.e., small for gestational age, Turner 
or Prader–Willi syndromes; Childhood Cancer Survivors, and those with childhood-onset growth 
hormone deficiency.
Methods: An expert panel meeting comprised of European paediatric and adult 
endocrinologists was convened to explore the current gaps in managing the healthcare of 
patients with endocrine diseases during transition from paediatric to adult care settings.
Results: While a consensus was reached that a team approach is best, discussions revealed 
that a ‘one size fits all’ model for transition is largely unsuccessful in these patients. They 
need more tailored care during adolescence to prevent complications like failure to achieve 
target adult height, reduced bone mineral density, morbid obesity, metabolic perturbations 
(obesity and body composition), inappropriate/inadequate puberty, compromised fertility, 
diminished quality of life and failure to adapt to the demands of adult life. Sometimes it is 
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difficult for young people to detach emotionally from their paediatric endocrinologist and/
or the abrupt change from an environment of parental responsibility to one of autonomy. 
Discussions about impending transition and healthcare autonomy should begin in early 
adolescence and continue throughout young adulthood to ensure seamless continuum of 
care and optimal treatment outcomes.
Conclusions: Even amongst a group of healthcare professionals with a great interest in 
improving transition services for patients with endocrine diseases, there is still much work to be 
done to improve the quality of healthcare for transition patients.
Introduction
Monumental changes in human development occur 
during adolescence. Teens undergo a period of physical 
growth and sexual maturation, and pronounced cognitive 
development, and are eagerly forming their own identities 
to achieve independence from parents, establish adult 
relationships apart from their families, and find a 
vocation. It is a time that can be difficult to navigate for 
healthy children, but for adolescents with chronic health 
issues, the challenges can be exacerbated. At a time when 
patients want most to fit in with their peers, endocrine 
disorders that are not optimally managed may render 
patients with short stature, stunted puberty and sexual 
maturation, morbid obesity, and metabolic abnormalities.
Paediatric and adult endocrinologists and nurse 
specialists were invited to attend an expert meeting in 
Vienna, Austria, on 5–6 June 2015 entitled ‘Bridging the 
Gap: Metabolic and Endocrine Care of Patients during 
Transition’ to discuss and share how transitional care is 
being managed within various institutions (i.e., personal 
referrals vs informal clinics vs formal transition/adolescent 
centres) and to identify factors that are most critical 
for effective transition to occur without interruption 
of the patient’s continuum of care (e.g., financial and 
reimbursement issues; hospital administration support; 
and needs for patient support groups, more scientific 
data, and/or colleagues dedicated to transitional care). 
The care for patients with childhood-onset GH deficiency 
(CO-GHD), those born small for gestational age (SGA), 
girls with Turner syndrome (TS), patients with Prader–
Willi syndrome (PWS), and survivors of cancers treated 
during childhood was addressed and, specifically, the 
role for GH therapy in patients with CO-GHD. Small-
group breakout sessions also permitted discovery and 
discussion of uncovered perceptions about the role 
of paediatric vs adult endocrinologists in managing 
transition patients.
Figure 1
Numbers and geographical locations of delegates.
• Austria 9
• Belgium 7
• Bosnia and Herzegovina 2
• Denmark 1
• Croaa 2
• Finland 4
• France 7
• Germany 5
• Greece 1
• Hungary 4
• Ireland 6
• Israel 6
• Italy 11
• Japan 1
• Lithuania 3
• Netherlands 7
• Portugal 5
• Serbia 4
• Slovakia 2
• Slovenia 3
• Spain 14
• Sweden 3
• Switzerland 2
• Turkey 1
• United Kingdom 20
• TOTAL: 100
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Materials and methods
A total of 130 delegates representing 25 different countries 
attended the meeting (Fig. 1) with an approximate 2:1 ratio 
of paediatric to adult endocrinologists and approximately 
4% nurse specialists (Fig.  2). The Scientific Planning 
Committee (SPC) was comprised of six experts in the field 
of endocrinology, who provided scientific and planning 
oversight for the overall programme and content. In 
addition, 13 faculty members presented at the meeting 
and 4 delegates moderated the breakout workshops.
The meeting was divided into three scientific 
sessions, grouped by content. Session I centred around 
the use of GH therapy during transition and beyond, 
including who, why and how to treat patients with GH. 
Session II was focused on why and how to follow-up and 
treat adolescent patients with TS and PWS. And in the 
last session, discussions dealt with the management of 
resulting endocrinopathies following cancer treatment 
during childhood. In addition, there were three 
breakout workshops designed to facilitate interactive 
discussions. Delegates were randomly separated into 
groups, each with a moderator, and given specific 
questions relating to the previous session’s topics to 
debate. A delegate from each workshop was selected by 
their peers to present a summary of their answers to 
the other attendees upon reconvening in the general 
session. Throughout the meeting, questions were asked 
of the delegates and their answers were recorded, 
analysed and projected to the audience by use of an 
Audience Response System.
Paediatric endocrinologist
Adult endocrinologist
Specialty nurse
30.6%
4.1%
65.3%
Figure 2
Delegate breakdown by specialty.
Table 1 Critical steps in transition.
Steps Actions Ref.
1. Ask young people and their 
parents
 • Inquire about patients’ feelings and concerns
 • Understand patients’ needs to balance independence with continued care and 
education
 • Solicit desired outcomes after transfer
 • Discuss transfer specifics (early preparation and clinic location)
(3)
2. Engage/train colleagues  • Different perceptions of levels of competency and involvement of paediatric vs 
adult physicians during transition care
 • Lack of training and inadequate resources are main barriers to successful 
transition service
(4)
3. Choose a clinic structure  • Multidisciplinary collaboration across all health sectors, including primary and 
secondary care, enhances successful transfer of care
(5)
4. Structured transition programme  • Requested by adolescents with discussions starting early in disease course, 
possibly soon after diagnosis
 • Example of successful generic transition programme is ‘Ready Steady Go’, 
implemented within a large National Health Service teaching hospital in the 
UK
(3)
(6)
(7)
5. Help with navigation  • Both hands-on and hands-off approach beneficial; a transitional care 
coordinator can assist with young people navigating transition and transfer 
and access to adult services
(8)
6. Monitoring  • Useful tools to monitor successful outcomes can include evaluation of specific 
disease markers (e.g., HbA1c), quality-of-life questionnaires, monitoring of 
attendance/adherence at clinic visits and reduced morbidity/mortality
(9)
7. Engaging the disengaged  • Get adolescents involved in monitoring and design; use technology-based 
transition interventions designed for adolescents with diverse chronic illnesses
(10) 
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Results
Dr Allan Colver (UK), a paediatric specialist on the 
transition of adolescents with complex health needs 
from child to adult services, kicked off the meeting 
by highlighting the monumental developmental 
changes that occur in the adolescent brain during ages 
11–25 years. He explained how these changes may impact 
the continuum of healthcare at a critical time when these 
young patients are seeking independence from their 
parents and beginning to navigate adult relationships 
and vocations (1). Understanding these complexities is 
key for achieving the following aspirations of transition, 
‘the optimal goal is to provide care that is uninterrupted, 
coordinated, developmentally appropriate, psychosocially 
sound and comprehensive’ (2). Key elements to 
enhancing adolescent healthcare include conducting 
consultations with patients apart from their parents and 
an emphasis on physician–patient confidentiality so that 
teens feel comfortable discussing topics like drug use and 
misuse, and sexual health. In addition, flexibility with 
methods of communication including expanded clinic 
hours to accommodate school and college schedules and 
willingness to use non-traditional contact methods (i.e., 
texting, email messaging and phone/video calls) may 
enhance adolescent engagement. Using transition models 
in other chronic diseases such as diabetes, juvenile 
arthritis and cystic fibrosis, Dr Helena Gleeson (UK) 
provided a ‘road map’ of key initiatives that have proven 
to be effective when transitioning young people to adult 
care (Table 1).
Both adult and paediatric endocrinologists are faced 
with similar uncertainties when managing the care of 
transition patients with GH abnormalities. They must 
consider which patients to test and what test to use for 
determining continued GH deficiency (GHD) and then 
decide which patients could benefit from continued 
treatment, and whether continued treatment is safe. Data 
presented in the first scientific session largely support the 
role of GH therapy during the period of transition and 
beyond. Patients with childhood-onset hypopituitarism, 
who have severe GHD and low insulin-like growth 
factor-I (IGF-I) levels, are likely to have permanent GHD. 
Testing should be undertaken after at least one month 
after discontinuation of GH therapy and patients with 
discordant tests or those at risk of permanent GHD 
should be carefully followed for either progressive 
deterioration or potential recovery of pituitary function 
over time (11, 12). Following attainment of adult height, 
additional benefits of GH therapy include improved body 
composition and bone mineral density (Fig.  3), as well 
as improved lipid profiles and improved quality of life 
(QoL) measures. A delay in continuing GH therapy in 
young adults with CO-GHD appears to negatively impact 
many of these effects. One major issue that has been 
the focus of numerous studies and in-depth discussions 
amongst the various endocrine societies is the safety 
of continued GH therapy (13, 14). Dr Lars Sävendahl 
presented a critical and in-depth overview of recently 
published papers on long-term safety evaluations based 
on analyses of various European registries participating 
in the Safety and Appropriateness of GH treatments 
in Europe (SAGhE) consortium (i.e., Belgium, France, 
Germany, Italy, the Netherlands, Sweden, Switzerland 
and the United Kingdom). The session concluded that 
while awaiting the final results of the whole SAGhE 
consortium, patients may continue GH treatment safely, 
a position that is consistent with statements released by 
the various societies including the European Society for 
Paediatric Endocrinology (ESPE), the Endocrine Society 
(ENDO), and the Pediatric Endocrine Society (PES). 
During the first workshop, each breakout group was 
asked a series of questions about the topics discussed in 
Session I to get a better understanding of actual clinical 
practices. The majority of delegates believed that it was 
the responsibility of the paediatric endocrinologist to 
perform the re-testing of continuing GHD into adulthood. 
However, some delegates thought that since the adult 
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Figure 3
Effects of discontinuation, continuation, and recommencement of GH 
replacement therapy on bone mineral density and body composition in 
the transition period (12). FM, fat mass; LBM, lean body mass; TB BMC, 
total body bone mineral content.
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endocrinologist would be making the decision whether 
or not to continue GH therapy in adulthood, they 
should be the ones to conduct the re-testing. In terms of 
which patients to test, responses varied. Some delegates 
recommended always testing patients with partial or 
severe GHD, while others recommended stopping GH 
therapy for one month and then re-testing all patients 
whose IGF-I levels were abnormal (and not attributable 
to other concurrent organic or genetic disease). If 
physicians were torn between deciding whether or not 
to re-rest, delegates recommended erring on the side of 
safety and performing GH stimulation testing. Delegates 
used the insulin tolerance test, arginine, glucagon, or 
arginine–GH releasing hormone stimulation testing. 
They stressed that testing physicians use the test that they 
are most comfortable administering and interpreting. 
Many delegates reported a lack of formal transitional 
centres, but relied, instead, on informal discussions with 
colleagues or personal referrals when transitioning from 
paediatric to adult care. When deciding how GH therapy 
should be managed and which parameters should be 
monitored, there was near-unanimous agreement that 
IGF-I levels should be evaluated, but delegates also 
stressed the importance of monitoring bone mineral 
density (BMD) and lipid profiles, and some physicians 
also assess fasting glucose/glycated haemoglobin levels 
(HbA1c) and QoL measures.
The second scientific session of the meeting explored 
transitional care of patients with TS and PWS from the 
perspectives of both paediatric and adult endocrinologists 
and how to manage children at risk for metabolic 
syndrome beyond adolescence. Some girls with TS are 
plagued by decreased adult height, gonadal dysgenesis, 
endocrine disturbances, cardiovascular abnormalities 
and psychosocial problems. Successful navigation from 
paediatric to adult care is particularly difficult in these 
patients who need life-long follow-up and screening. 
Comprehensive summaries of issues on medical care 
in patients with TS have been published that provide 
helpful checklists for use in clinical practice (16, 17, 18, 
19). One of the main goals during adolescence is to mimic 
physiological puberty, so the current recommendation is 
to begin oestrogen therapy around the ages of 11–12 years 
in the presence of suspected ovarian failure. Additional 
data are needed to determine the optimal dosage 
or whether starting oestrogen therapy earlier would 
convey additional benefit. Growth hormone therapy, at 
supraphysiological doses, can improve adult height (gain 
of approximately 8 cm) with early treatment, preventing 
short stature in the majority of patients. Improvement in 
adult height is superior when administered earlier rather 
than later in the course of the condition (20). Patients 
should be screened for cardiovascular abnormalities 
with mandatory regular follow-up visits. Hormone 
replacement therapy in patients with TS improves BMD, 
blood pressure and liver enzymes with no set ‘window of 
opportunity’ for administration (13, 14, 15, 16, 17, 18, 19, 
20, 21, 22, 23). Screening of adolescent and adult patients 
should include cardiac evaluations (blood pressure, 
auscultation, echocardiography and MRI); thyroid status; 
metabolic health (body mass index, level of physical 
exercise and diet, blood sugar and lipid profile levels, and 
liver enzymes); BMD (osteoporosis surveillance); hearing; 
and urinary testing. Both paediatric and adult physicians 
agree that treatment clinics should be multidisciplinary, 
but anchored in one department. What remains unclear 
is how best to implement the recommended care in 
adult women with TS, many of whom are lost during the 
transitional period.
Patients with PWS share many similarities with 
patients diagnosed with GHD. Patients with PWS 
present with a host of disorders (i.e., multiple hormone 
deficiencies, hyperphagia, obesity, sleep apnoea, 
intellectual disabilities, and behavioural and psychiatric 
issues), many of which appear, or worsen, during 
adolescence. Optimal healthcare management during 
this critical time requires a multidisciplinary transition 
team. Dr Maithé Tauber, director of the Reference Centre 
for PWS in France, includes both the paediatrician and 
the adult endocrinologist during the entire transition 
process. Through a minimum of three visits, two in the 
paediatric setting and one visit in the adult setting with 
both paediatric and adult physicians attending, patients 
are transitioned to adult care (Table 2).
Several studies report an insufficient rise in GH upon 
stimulation (8–67%) and low IGF-I levels in the majority 
of adult patients (75–91%) with PWS indicating reduced 
activity of the GH/IGF-I axis (24, 25, 26). There are 
conflicting results regarding GHD in adult patients with 
PWS with more recent papers reporting fewer cases of 
GHD, perhaps due in part to fewer morbidly obese patients. 
While hormone replacement therapy does not change 
the intrinsic abnormalities of PWS, treatment with GH 
improves body composition, physical fitness, bone size 
and strength, and QoL (27). Clinical experience suggests 
a positive response with replacement of sex steroids, 
confirmed in men with PWS in the only treatment trial 
conducted to date (28). Strict diet and regular physical 
exercise also play key roles in overall patient health. Early 
diagnosis, combined with multidisciplinary care including 
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GH replacement and use of other hormonal therapies, 
can ease PWS complications, ameliorate comorbidities, 
and improve QoL and transition to adult life in these 
patients (29). However, additional studies with hormone 
replacement, particularly during transition, are needed.
The role of GH therapy in children born small for 
gestational age (SGA) has been well documented to be 
effective at increasing linear growth and improving 
body composition. Growth hormone therapy in these 
children can also induce higher insulin levels which led 
to speculation that these patients may be at increased risk 
for development of metabolic syndrome. However, studies 
have shown that in children born SGA, GH-induced 
insulin insensitivity disappeared after discontinuation 
of GH, at least after 6  years of discontinuation of GH 
therapy (30). In addition, the beneficial effects of GH 
therapy on systolic and diastolic blood pressure indices 
and serum lipids remained unchanged even after 6 years 
of discontinuation of GH therapy (31). Children are 
followed up regularly while receiving GH therapy; 
however, beyond adolescence, knowledge is limited 
as to how often to monitor these patients. Long-term 
follow-up data are required to make recommendations 
during transition and adulthood, but it is imperative to 
remind SGA patients not to become overweight or obese 
and to seek low-threshold clinical care in the presence 
of fatigue, weight gain, and a family history of diabetes, 
cardiovascular disease or hypertension.
The goals of the second breakout workshop were 
to garner information on current clinical practices with 
regard to treatment and follow-up of patients with TS 
and PWS. The majority of delegates reported that in their 
centres/hospitals, adult endocrinologists lead the 
management of patients with TS when they emerge 
from paediatric endocrine care, but with input from 
a multidisciplinary team including gynaecologists, 
cardiologists, general practitioners and psychologists. While 
published guidelines on the management of TS patients 
exist, treating physicians must stay abreast of the most 
recent publications to ensure adherence. Fertility in these 
patients is an important issue and the consensus was to begin 
discussions with patients beginning around ages 11–12 years, 
depending on their maturity level, using simple terms. 
Additional specialists, i.e., obstetricians/gynaecologists, 
geneticists, etc., may be included in these conversations to 
provide robust information. Hormone replacement therapy 
should be individualised, but in most patients, treatment 
should be started at low doses and increased slowly over a 
2-year time period to mimic physiological puberty. Many 
delegates prefer the use of transdermal patches and then 
switch to oral medications as the patient matures.
Decisions about whether to continue GH therapy after 
adult height attainment in adolescents and adults and how 
best to evaluate the hypothalamic/pituitary/gonadal axis 
in patients with PWS were not so straightforward. While 
the majority of responders assume that continuing GH 
therapy may result in increased adult height and improved 
lean body mass, exercise capacity, QoL and BMD, some are 
concerned about the effects of GH on insulin resistance 
and diabetes in adolescent and adult with PWS. With a 
lack of substantive data and the fact that GH therapy is 
non-reimbursable in many countries after attainment of 
adult height, delegates suggested monitoring IGF-I levels, 
especially in patients with confirmed GHD at transition, 
Table 2 Example of successful steps in transition of patients with PWS.
Visit Clinic setting Actions
1 Paediatric  • Paediatrician assesses adult height and patient undergoes multidisciplinary evaluation  
(i.e., rheumatologist, cardiologist, psychologist, etc.)
 • Adult endocrinologist receives oral summary of the patient’s medical history and detailed description 
of the present situation (including medical examination, socio-educational aspects of the situation, 
psychological and relational issues, medical therapies, family structure, etc.)
 • Patients are given opportunity to talk with physicians alone, without parents, to voice concerns about 
sexual and reproductive issues, psychological difficulties, and autonomy in everyday life
2 Paediatric  • Can comprise multiple visits
 • Visits occur every 6 months and include complete medical check-up
 • Through joint decision by physicians, patient, and their family, date is set for first visit in adult 
endocrinology unit; could be as soon as 6 months or up to 2 years later, depending on complexity of 
the situation and patient’s readiness for transition
 • Whenever patient is ready for first ‘adult’ visit, paediatrician sends complete medical report to adult 
clinic and sets appointment
3 
 
Adult 
 
 • Evaluation performed during last transition visit is similar to the other check-ups undertaken in 
paediatric unit; primary difference is environmental: s/he is now considered an adult and begins 
management under care of adult specialists
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evaluating gonadotropin levels, and watching for early 
signs of obesity development, increasing hypotonia, 
decreased QoL, and a low activity level.
The third and last scientific session of the meeting 
focused on patients with endocrine sequelae as a 
result of craniopharyngiomas or cancer therapy 
administered during childhood. Dr Hermann Müller 
opened the session with a discussion of the challenges 
in the treatment of patients with craniopharyngiomas 
(CPs). Since childhood-onset CPs often affect the 
hypothalamic and pituitary regions as well as the optic 
chiasm, regardless of the degree of resection, patients 
frequently experience relapse and progression events 
during long-term follow-up. For these reasons, treatment 
of CP should be viewed as chronic (32). During initial 
diagnosis, experienced multidisciplinary teams should 
formulate treatment plans for postoperative follow-up 
and rehabilitation. Gross total resections should be 
avoided in cases of hypothalamic involvement in an 
effort to spare any further damage to the sensitive region 
(32). And since endocrinopathies are relevant causes 
of death in patients with CPs (33, 34), it is extremely 
important for patient health to be guided and monitored 
by an endocrinologist.
The last group of patients discussed in this meeting 
were survivors of childhood cancers and how to treat 
and manage endocrine sequelae during transition and 
into young adulthood. While advances in anticancer 
treatments have greatly increased survival in children, 
the damage of these therapies to organ systems may 
not be evident for many years (35). Data from the 
Childhood Cancer Survivors Study, a large, multi-
centred, retrospective study comprised of adults who 
have survived for at least 5  years post cancer therapy, 
have shown a high risk for chronic health conditions. 
The rates are especially high for endocrinopathies, i.e., 
premature gonadal failure, thyroid disease, osteoporosis, 
and hypothalamic and pituitary dysfunction (35). Of 
paramount importance to many adolescents and their 
families is the implication of neoplastic therapy on 
future fertility. While cryopreservation of sperm is 
widely used in males undergoing oncologic therapy, 
options for preservation of fertility in female patients 
are more complex (36). Treating physicians should 
Table 3 Hurdles and solutions in achieving cohesive and seamless transitional care.
Transition team member Possible viewpoints Possible solutions
Paediatric endocrinologist Might think that:
 • Adult endocrinologists are not 
cognisant of the complexity of the 
problem
 • Adult endocrinologists are not willing 
to provide adequate time for visits/
discussion
 • All providers need to work together to craft 
developmentally appropriate healthcare so 
young patients become more knowledgeable and 
responsible for managing their conditions
 • Emphasise physician–patient confidentiality so that 
teens feel comfortable discussing topics like drug 
use, misuse, and sexual health
Adult endocrinologist Might think that:
 • Paediatric endocrinologists are 
overprotective and do not sufficiently 
prepare paediatric patient for move 
to adult care
 • All providers must agree to sharing information 
and recognising that some overlap is necessary for a 
seamless conversion
 • Willing to be flexible with methods of 
communication with transition patients, e.g., 
expanded clinic hours to accommodate school/
college schedules; use of non-traditional contact 
methods (email, text)
Parents  • Parents may be unwilling to readily 
trust a new provider, especially if the 
adult endocrinologist has not been 
involved in transitional plan
 • Parental trust issues can influence the 
young person
 • Include parents in transition process to witness 
growth of relationship between child and provider 
and ease concerns about turning over the primary 
responsibility of healthcare management to patient
Young people 
 
 
 
 
 
 
 
 • Young people have become 
accustomed to allowing parents to 
manage healthcare consideration
 • Young people may feel that 
paediatric endocrinologists have 
known them and their medical 
condition for many years and are, 
therefore, more knowledgeable than 
the new adult endocrinology provider
 • Young people need to become more involved in 
making healthcare decisions so that they become 
more adept at managing their disease 
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implement discussions early on so that families can 
determine the best options for fertility preservation. 
It is important to remember that obesity and gonadal 
function are intrinsically linked and perturbations 
of either can adversely affect the other (37, 38). The 
risk of developing metabolic syndrome is also high 
in Childhood Cancer Survivors (CCS), particularly in 
patients who have received radiation therapy. Patients 
who have received cranial radiotherapy (CRT) are at 
higher risk for anterior hypopituitarism (39). A report 
from the St Jude Lifetime Cohort study found that in 
748 CCS treated with CRT, 348 had an IGF-I standard 
deviation score (SDS) <−2 indicating a prevalence of 
severe GHD in nearly 50%. And of those severe GHD 
patients, only one was receiving GH therapy. Untreated 
GHD results in significantly decreased muscle mass and 
exercise tolerance, increased abdominal obesity, low 
energy expenditure, muscle weakness, and impaired 
QoL. In this study, the impairment was related primarily 
to the GHD rather than the original cancer diagnosis 
and treatment. Reassessment of GH status should be 
mandatory after achievement of adult height in all 
patients who received GH therapy during childhood for 
radiotherapy-induced GHD. While this strategy should 
be effective at identifying many of the patients with 
severe GHD, guidelines still need to be developed for 
repeated retesting of GH status in patients with mild-to-
moderate GHD at adult height.
During the last breakout workshop, delegates 
discussed and debated follow-up and treatment in CCS. 
While everyone agreed that these patients should have 
long-term follow-up by an adult endocrinologist, there 
was debate about the frequency of the visits. Timing 
can depend on the type of cancer and antineoplastic 
treatments administered and, in some countries, the 
frequency may be dictated by healthcare coverage. 
During the follow-up visits, routine tests should 
include a physical examination, anterior pituitary 
hormone function, thyroid hormone assessment, 
metabolism (BMI, lipid profile, glycated haemoglobin, 
glucose levels, etc.), assessments of QoL, bone mineral 
density, and fertility parameters. Additional tests may 
be necessary based on type of cancer and therapies 
administered, e.g., assessment of cardiac function 
in patients who received cardiotoxic regimens. GH 
replacement in patients found to be GH-deficient 
is generally considered safe with follow-up similar 
to other adults with GHD (13). When transitioning 
from a paediatric endocrinologist to adult internist–
endocrinologist, it is also important that the specialists 
work together as a team to ensure that adult providers 
have a clear and detailed medical history including a 
summary of previous treatments so as to anticipate/
plan for future complications. It is also beneficial 
if the paediatric oncologists begin discussions with 
their patients about fertility, stress the importance 
Table 4 Factors contributing to successful transitional healthcare.
Disease-specific considerations (GHD, PWS, TS, SGA, CCS) Generic considerations
 • Identify which patients to test for endocrine 
dysfunction and which would benefit from GH 
replacement
 • Decide which stimulation test to use
 • Use specific disease markers to gauge successful 
intervention, i.e., IGF-I levels, BMD, lipid profiles, 
and possibly HbA1c and QoL measures
 • Aim to improve adult height, normalise body 
composition, and bone density
 • Preserve fertility (particularly for patients with TS 
or CCS)
 • Determine timing of subsequent follow-up visits 
once GH therapy is stopped 
 
 
 
 
 
 
 
 • Be approachable and welcoming; adolescents like eye contact, facial 
expressions, friendliness
 • Make the clinic environment more youth friendly, i.e., relaxed dress 
code for providers, availability of magazines/television channels geared 
towards young adults
 • Permit consultations with adolescents alone, clearly emphasise 
confidentiality, and tell patients what to expect in age-appropriate 
terms
 • Be willing to hear concerns about sexual health, substance abuse and 
mental health issues
 • Institute flexible access, i.e., extended clinic hours to accommodate 
school/job schedules, and use of email/texting/video chats
 • Avoid having young adults make key decisions at times of excitement 
or stress (i.e., holidays, final examinations, etc.)
 • Remember that healthcare is just one of many concerns for the young 
patient as they are also dealing with education, budding sexuality, 
separation from parents, navigating friendships, etc.
 • Engage young adults in self-management education and skills training
 • Work to establish joint provider sessions involving members from 
paediatric and adult treatment teams
 • Utilise a transition coordinator and/or specialised young adult clinics
BMD, bone mineral density; CCS, childhood cancer survivors; GHD, GH deficiency; IGF-I, insulin-like growth factor I; PWS, Prader–Willi syndrome; QoL, 
quality of life; SGA, small for gestational age; TS, Turner syndrome.
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of maintaining a healthy weight and balanced diet, 
and introduce the concept that survival often comes 
with a price (a lifelong commitment to carefully 
monitoring their health with the expectation that 
side effects of their disease and/or treatments are 
likely). Ideally, members of the transition team would 
include paediatric oncologists and radiotherapists 
who understand the long-term consequences of 
antineoplastic therapies; psychologists who can 
help patients deal emotionally with very complex 
diseases; paediatric and adult endocrinologists who 
can provide follow-up and navigate hormonal issues; 
reproductive health specialists, nurse specialists to aid 
in coordinating care, dieticians to help patients manage 
their weight and diet; and social workers to provide 
assistance with reimbursement and employment.
Guidelines for transitional care for adolescents with 
endocrine and metabolic disorders can be modelled after 
transitional care programs for other chronic diseases. 
Successful programs have included courses for adolescents 
on self-management education, skills training, joint 
provider sessions involving members from the both 
paediatric and adult treatment teams, use of a transition 
coordinator, and utilisation of specialised young adult 
clinics (40, 41, 42, 43). Non-institutional barriers to 
successful transition can include a host of perceptions 
about the roles and responsibilities of the adult vs the 
paediatric endocrinologists, beliefs held by the parents, 
and expectations of the patients (Table 3).
While many paediatric providers and parents feel that 
delaying transition until after completion at university 
permits continuity of care, post-transition surveys from 
young adults indicated that young people felt more 
independent and in charge of their disease during this time 
and that their new adult providers were more supportive 
of their decision-making and autonomy (44). While 
transition should begin in early adolescence (11–13 years 
of age) at the latest, deciding ‘when’ to transfer should 
depend largely on the readiness of the young person 
including their preferences, their level of independence 
in healthcare, and various condition factors. In addition, 
it would be beneficial to establish a relationship with an 
adult provider before issues of adulthood (e.g., stress of 
hospitalisation, pregnancy, etc.) force a meeting in less 
than favourable circumstances.
Throughout this specialty meeting, delegates have 
shared their experiences and ideas about transitional 
healthcare primarily in the background of various 
endocrinopathies. However, there are a number of factors 
for providers to consider incorporating into whatever 
model of transitional care they are using, regardless of 
patient diagnosis (Table 4).
Discussion
We have learned that even amongst a group of healthcare 
professionals who have an interest in improving 
transition services for patients with endocrine diseases, 
there is still much work to be done to improve the 
quality of healthcare for patients moving from paediatric 
to adult care. While the principles of quality healthcare 
during transition are the same for all young people, 
regardless of endocrine condition, methods of transition 
(i.e., informal discussions, formal transition centres, 
etc.) can differ amongst young people. Paediatric and 
adult endocrinologists must be willing to work together, 
sharing information and recognising that some overlap 
is necessary for a seamless conversion. Adolescent 
patients need developmentally appropriate healthcare 
to become more knowledgeable and responsible for 
managing their disease. And parents need to be included 
in the transition process to witness the growth of the 
relationships between their child and his/her providers 
so that they develop a level of confidence in ultimately 
turning over the primary responsibility of healthcare 
management to the patient. Whether through 
development of a standardised referral system, informal 
discussions amongst colleagues, or establishment of 
formal transition centres, all gap-bridging efforts are 
welcome to ensure that the needs of adolescents with 
chronic endocrine conditions are being met.
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